R3I1 Stock Overview
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Advanced Oncotherapy plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.021 |
| 52 Week High | UK£0.27 |
| 52 Week Low | UK£0.0085 |
| Beta | 0.063 |
| 1 Month Change | 0% |
| 3 Month Change | -14.00% |
| 1 Year Change | -91.92% |
| 3 Year Change | -93.20% |
| 5 Year Change | -95.40% |
| Change since IPO | -96.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| R3I1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.0% | -1.2% |
| 1Y | -91.9% | -3.7% | 1.2% |
Return vs Industry: R3I1 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: R3I1 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| R3I1 volatility | |
|---|---|
| R3I1 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: R3I1's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine R3I1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 174 | Nicolas Serandour | www.avoplc.com |
Advanced Oncotherapy plc, together with its subsidiaries, engages in the designing, assembling, and selling proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also engages in the management of healthcare related properties.
Advanced Oncotherapy plc Fundamentals Summary
| R3I1 fundamental statistics | |
|---|---|
| Market cap | €10.95m |
| Earnings (TTM) | -€37.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs R3I1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| R3I1 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£32.60m |
| Earnings | -UK£32.60m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.06 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 39.6% |
How did R3I1 perform over the long term?
See historical performance and comparison